Approved treatments
for IgaN

Fabhalta

Fabhalta (iptacopan) is an oral therapy approved to preserve kidney function in adults with immunoglobulin A nephropathy (IgAN) who are at risk of disease progression. It is taken as oral capsules twice daily.

Learn more

Filspari

Filspari is an oral therapy approved to slow the decline in kidney function in adults with primary immunoglobulin A nephropathy (IgAN). It is taken as oral tablets once daily.

Learn more

Tarpeyo

Tarpeyo is an oral therapy approved to slow the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of disease progression. It is taken daily in the form of oral capsules for nine months.

Learn more

Trutakna

Trutakna is an injection therapy approved to treat adults with immunoglobulin A nephropathy (IgAN) who are at a high risk of disease progression. It is given via under-the-skin injections once weekly.

Learn more

Ultomiris

Ultomiris (ravulizumab) is an approved treatment for adults with IgAN who are at risk of disease progression. Delivered via infusions into the bloodstream every eight weeks, the medication is designed to block an immune pathway that contributes to kidney damage in IgAN.

Learn more

Vanrafia

Vanrafia is an oral therapy approved for adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of rapid disease progression. It is taken in the form of oral tablets once daily.

Learn more

Voyxact

Voyxact is an injectable therapy approved to reduce excessive protein in the urine (proteinuria) for adults with immunoglobulin A nephropathy who are at risk of disease progression. It is given as a monthly injection under the skin.

Learn more